Article Correctness Is Author's Responsibility: SHINE and IOCB Prague enter Lu-177 process license agreement

(Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague)) SHINE Medical Technologies, Inc. and IOCB Prague have entered into an intellectual property license agreement providing SHINE with a global, exclusive license to a novel method for separating rare earth elements. SHINE will use the innovation to produce lutetium-177 (Lu-177) for the treatment of cancer. The separation technique was developed by the team of Dr. Miloslav Polášek, from IOCB Prague.